Prednisolone acetate/Tobramycin

醋酸泼尼松龙/妥布霉素

Report date: 2022/07/19 16:22:54

Base Information

Drug NamePrednisolone acetate/Tobramycin
Drug Alias NamePrednisolone acetate●tobramycin醋酸泼尼松龙-妥布霉素醋酸泼尼松龙●妥布霉素Prednisolone acetate and tobramycin醋酸泼尼松龙+妥布霉素 +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of Action30S ribosomal subunit inhibitorsGlucocorticoid receptor agonists
TargetsGlucocorticoid receptor30S ribosomal subunit
Therapy Area/IndicationsPostoperative ComplicationsCataractEye Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes PrednisoloneTobramycin
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBausch Health Companies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBausch & Lomb Incorporated
Active IndicationsN/A
Inactive IndicationsPostoperative ComplicationsCataractEye Infections

Other Information

ATC CodeN/A
Related LinksN/A